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ABSTRACT 
Following certain types of perinatal or adult-onset brain damage 
spasticity is the common feature. A persons's disability can be greatly 
increased secondary to spasticity, which may present a major problem 
in the restoration of motor function. 
Depending on the cause and location of brain injury, the clinical 
characteristics of spasticity can vary in signs and severity. These varying 
signs include flexor spasms in the patient with the spinal injury, dystonic 
posturing in the patient with hemiplegia and spastic diplegia in the child 
with cerebral palsy. It is apparent that many factors are involved with 
augmented reflexes and the list of possible sources is incomplete. 
Spasticity in stroke, spinal cord injury, and traumatic brain injury often 
interferes with function, limits independence and can result in secondary 
complications such as contractures. Considering the variety of problems 
associated with spasticity, it is unlikely that one agent will be beneficial to 
all patients. Because it takes normal muscle tone and normal control of 
the tone to give rise to normal movement, therapeutic intervention is 
often necessary and the type of intervention chosen to 
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treat a person's spasticity is best individualized for each person. 
Two treatment methods currently used are Botox injections and 
selective dorsal rhizotomy. The purpose of this study is to review the 
literature on Botox injections and selective dorsal rhizotomy in the 
treatment of spasticity. This information will hopefully aid therapists in 




Following certain types of perinatal or adult - onset brain damage, 
spasticity is the common feature. Spasticity is defined as "a motor 
disorder characterized by a velocity-dependent increase in tonic stretch 
reflexes (muscle tone) with exaggerated tendon jerks, resulting from 
hyper- excitability of the stretch reflex, as one component of the upper 
motor neuron syndrome." 1 
A person's disability can be greatly increased secondary to 
spasticity, which may present a major problem in the restoration of motor 
function.2 Depending on the cause and location of brain injury, the 
clinical characteristics of spasticity can vary in signs and severity.3 These 
varying signs include flexor spasms in the patient who has a spinal cord 
injury, dystonic posturing in the patient who has hemiplegia resulting from 
a stroke, and spastic diplegia in the child with cerebral palsy.4 It is 
apparent that many factors are involved with augmented reflexes and 
the list of possible sources is incomplete. 
Spasticity in stroke, spinal cord injury, and traumatic brain injury 
often interferes with function, limits independence and can result in 
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secondary complications such as contractures.2 Considering the variety 
of problems associated with spasticity, it is unlikely that one agent will be 
beneficial to all patients.4 Because it takes normal muscle tone and 
normal control of the tone to give rise to normal movement, therapeutic 
intervention is often necessary and the type of intervention chosen to 
treat a person's spasticity is best individualized for each person.5 
Two treatment methods currently used to treat spasticity are Botox 
injections and selective dorsal rhizotomy. The purpose of this study is to 
review current literature on Botox injections and selective dorsal 
rhizotomy in the treatment of spasticity. This review will include an 
examination of spasticity, a discussion of Botox injections, and a 
discussion of selective dorsal rhizotomy. This information will hopefully aid 




Before we can understand any type of treatment for spasticity, we 
must first try to understand what spasticity is and some of it's causes. 
Spasticity is more difficult to characterize than to recognize and still more 
difficult to quantify.l One widely accepted definition of spasticity is "a 
motor disorder characterized by a velocity-dependent increase in tonic 
stretch reflexes (muscle tone) with exaggerated tendon jerks, resulting 
from hyperexcitability of the stretch reflex, as one component of the 
upper motor neuron syndrome." 6 
Spasticity is caused by an injury to upper-motor neurons and 
diagnostically it is the hallmark of an upper-motor neuron disorder.1,3 
Spasticity is often a common feature following certain types of perinatal 
or adult-onset brain damage.7 Regardless of the age of onset of 
damage, accentuated alpha motor neuron discharge is present. Some 
of the neurophysiological variables, however, seem to show age-related 
differences. Reflex irradiation does not appear to be present following 




The clinical characteristics of spasticity can vary in signs and 
severity depending on the location and the cause of brain injury.3 There 
are four signs of spasticity. Two of the signs, hypertonicity and 
hyperactive deep tendon reflexes, must be present in order to diagnose 
spasticity while the remaining two signs, clonus and muscle spasms, are 
usually, but not always, present in a person experiencing spasticity. 
Hypertonicity, also known as increased muscle tone, is an 
involuntary resistance to a quick movement or stretch felt in an affected 
limb by an examiner.3 The tension between the origin and insertion of 
each muscle is referred to as muscle tone.8 Muscle tone can be defined 
as "the sensation of resistance felt as one manipulates a joint through a 
range of motion, with the subject attempting to relax."l Muscle tone 
consists of several distinct components: 1) physical inertia of the 
extremity, 2) mechanical-elastic characteristics of muscular and 
connective tissues, and 3) reflex muscle contraction (tonic stretch 
reflexes). Hyperactive tonic stretch reflexes are classic components of 
spasticity.8 Normal postural tone can be defined as "a state of 
readiness."s Muscle tone must be sufficiently high to provide support 
against gravity yet low enough to allow a person to move freely. 
5 
Normal movement requires normal muscle tone and normal control of 
the tone. 
Hyperactive deep tendon reflexes, resulting in a condition referred 
to as hyperreflexia, can be seen in individuals with spastic-type cerebral 
palsy as an accentuated myotatic (stretch) reflexes.7 This hyperactive 
reflex can also exhibit reflex irradiation where by one muscle group 
receives a tendon tap (e.g. quadriceps) and EMG potentials are seen in 
that muscle group as well as it's antagonist (Le. hamstrings). Hyperactive 
reflexes can also be seen in muscles at sites distant from the point of the 
tendon tap. When one has a loss of descending inhibition from higher 
centers due to some type of injury, the result can be reflex irradiation.7 
To be considered as a positive sign of hyperactive deep tendon reflex, 
there must be a decrease in the amount of stimulus needed to elicit a 
knee jerk or an exaggerated muscle response.3 
According to Howe and Oldham,5 "clonus is a series of repetitive 
muscle contractions elicited by a rapidly applied, but maintained, 
stretch."5 Clonus can often be elicited in the patient with spasticity by 
quickly initiating and then holding the foot in dorsiflexion. One will see a 
rhythmic contraction and partial relaxation of affected muscles in 
response to the sustained stretch.3 Clonus is believed to be the result of 
alteration of the normal pattern of motor neuron discharge.7 
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Spasms, according to Webster,9 are "an involuntary and 
abnormal contractions of muscle or muscle fibers." Spasms are often in 
response to a noxious stimulus.3 The triggering stimulus is from a visceral 
or cutaneous source making spasms unlike the other signs of spasticity 
which are triggered only by the stretch of skeletal muscle fibers. It is 
important to consider spasms as a sign of spasticity due to the fact that 
both spasticity, which is triggered by a muscle stretch, and spasms, 
proceeded by noxious stimulus, are often present in the same patient, 
although one or the other is usually dominant.3 The spasm can take the 
form of sudden flexion or extension. The form demonstrated depends on 
several factors, one being the site of the triggering stimulus. Whether 
flexion or extension is elicited depends greatly on which would be most 
protective to the body. The reflex becomes exaggerated due to lack of 
modification of the reflex by higher motor centers. Katz and Rymer! 
proposed the idea that changes in the intrinsic muscle mechanical 
properties (rather than stretch reflex enhancement) are largely 
responsible for spastic hypertonia. These possible neural mechanisms for 
spastic hypertonia include increased motor neuronal excitability via 
three ways. The first two ways are: 1) excitatory synaptic input is 
enhanced and 2) inhibitory synaptic input is reduced. The third way is by 
a change in the intrinsic electrical properties of the neuron or secondly 
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enhanced stretch-evoked synaptic excitation of motor neurons through 
1) hyperactivity of gamma efferent or 2) excitatory interneurons more 
sensitive to muscle afferent input. St. George3 proposed that spasticity 
occurs when there is lack of control of spinal reflex activity because of 
the upper motor neuron damage. It is apparent that many factors are 
involved regarding augmented reflexes and the list of possible sources is 
incomplete.1 
According to Howe and Oldham,s authors have attempted to 
grade spasticity but the quantification of spasticity is a challenging and 
difficult problem.1.2 Classification of spasticity has been based primarily 
on highly observer-dependent measurements with a concentration on 
tabulation of functional activities, biomechanical analysis of limb 
resistance to mechanical displacement, purified surface 
electromyographic responses to agitation, voluntary movement, gait 
analysis and other clinical measurements.1.2 Several systems have been 
composed to grade spasticity such as the Modified Ashworth Scale3 and 
the Clinical Scale for Spastic Hypertonia.1 Spasticity is ranked from mild 
to severe and the criteria for grading the severity of spasticity are not 
standardized, therefore there is no precise method for grading the 
severity of spasticity.3 The ability to quantify the presence and severity of 
spasticity can be essential to the understanding and treatment of this 
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disorder.2 However, since no standardized test of spasticity exists and the 
effect of abnormal tone on movement can be clearly seen, it may be 
appropriate to substitute a measurement of the 'quality' of movement.5 
Measuring the quality of movement can also be valuable in assessing 
the effects of a therapeutic interventions such as drug treatments or 
surgical procedures? A person's disability can be greatly increased 
secondary to spasticity, especially in an incompletely paralyzed person.8 
Spasticity is always present as part of a movement but is never confined 
to one muscle group.5 Flexor or adductor spasms may result from a 
release of reflexes from descending inhibitory contro!.l For example, a 
person with paraplegia may require the use of restraints in his wheelchair 
due to severe flexor spasms. 
Spasticity presents major problems in the restoration of motor 
function and because its presence is so predictable, it is reasonable to 
base therapies on the appearance of spasticity.5 "Scissoring" of the 
lower extremities may be the result of hip adductor spasms and may limit 
a patient's ability to ambulate effectively.l It is also important to realize 
when spasticity is beneficial to the patient in carrying out basic activities 
of daily living such as transferring. A person with mild spasticity can 
trigger extensor spasms in their legs that enables them to stand straight 
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while transferring into bed, thus making the transfer easier.3 Therefore it is 
important to note that reduction of spasticity does not necessarily result 
in functional gains.7 For therapeutic interventions, functional gains must 
be the goal. It is unlikely that one agent will be beneficial to all patients 
considering the variety of problems associated with spasticity. "The 
functional impairment due to spasticity must be carefully assessed 
before any treatment is considered.1I4 Therapeutic intervention should 
be individualized for each patient and therefore it is important to know 
the different options for intervention. 
CHAPTER 3 
BOTOX INJECTIONS 
"Clostridium botulinum" is a bacterium that causes a serious form 
of food poisoning. 10 The commercial name for this bacterium is "Botox". 
The paralytic neurotoxin has become widely investigated as a potential 
therapeutic treatment for a variety or neuromuscular disorders11 and due 
to the fact that in purified form, it is the first bacterial toxin to be used in 
medicine.12 Botox was initially used in the early 1980s to treat 
strabismusl2.13 (crossed eye) and blepharospasml-17 (squinting) and the 
Food and Drug Administration (FDA) licensed botulinum toxin as an 
oculinum in December 1989 for these two specific eye conditions.12 
Since 198618 Botox has also been used to treat spasmodic 
dysphonia,11.14.15.17.19.20.21 and is presently used to treat many other 
conditions which include spasmodic torticollis,11.15.17.22 cerebral palsy,17.23 
dystonia,12.15.24-27 myofascial pain syndrome,26 achalasia,28.29 hemifacial 
spasm,11.15.24 and progressive supranuclear palsy.30 Epperson19 reported 
Scott as pioneering the use of botulinum toxin for use as a chemical 
denervation of extraocular muscles, resulting in a new area in neurology 
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called "interventional neurology." 
The bacteria of Clostridium botulinum produces seven 12.19 or 
eight15.17.23 serologically distinct toxins that are potent neuroparalytic 
agents. The strains of toxin have been identified and labeled A through 
G12.15.17.19.23 with the eighth strain distinguished as C_2.15 The bacteria and 
spores are harmless, but the toxin produced by the bacteria, when they 
grow, are very dangerous.12 Botulinum toxins are considered the most 
poisonous substances known to humankind.12.15 This anaerobic organism, 
sometimes found in improperly canned food is a potentially lethal toxin.20 
The food poisoning, due to botulism, blocks the transmission of nerve 
impulse to a muscle and this results in muscle weakness, paralysis10 and 
ultimately death.12 Death occurs by suffocation as the botulism 
paralyzes the diaphragm and prevents the lungs from functioning.28 
Type A toxin, the most potent known biologic toxin, is easily crystallized 
and relatively stable.17 The toxin is supplied in vials in small amounts 
which make the administration of a fatal dose extremely difficult. 
In the clinic, when used in minute doses, Botox becomes a very 
effective means for relieving spasmodic symptoms.20 When small doses 
of the toxin are injected into the affected muscle,12 it acts 
presynaptically at the nerve terminals to prevent calcium dependent 20.30 
release of vesicle bound acetycholine. The process is not fully 
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understood but the toxin prevents exocytosis of neurotransmitter 
vesicles. 1s There are three hypothesized mechanisms a) inhibition of 
calcium influx during nerve stimulation, b) induction of calcium ion efflux 
and c) direct action of the toxin on acetycholine release at the nerve 
terminals.17 The final outcome is that effective neuromuscular control is 
blocked and a functionally denervated muscle results. Focal weakening 
and atrophy of the injected muscle is the final result of local Botox 
intramuscular injections. 
The most effective Botox dose per muscle is not known.31 For the 
treatment of blepharospasm, the recommended dose is 10-30U/eye 
whereas for Dysport, another trade name for botulinum toxin, it is 100-200 
U/eye. ll The lethal dose for an adult human is estimated at 5,OOOU.17 In 
a study done by Koman et al,17 initial dosage was determined on the 
basis of patient body weight and its distribution was based on the 
relative mass of the muscle causing deformity. Comella et al31 showed 
improvement was more significant in patients who received 
EMG-assisted Botox injections versus clinically assisted injections. The 
reason for greater improvements with EMG assistance is believed to be 
due to the increased accuracy in identifying overactive muscles. 
Koman et al 17 also reported on a protocal where pediatric patients 
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received small initial dosages of 1-2U/kg and dosages were increased at 
each subsequent follow-up evaluation until the target threshold for the 
desired muscle was reached. Threshold was defined as the dose of 
Botox necessary to a) eliminate dynamic deformity, b) allow antagonist 
muscle(s) to correct the dynamic deformity either partially or 
completely, or c) allow effective bracing. 
In the literature, there are a number of studies showing the positive 
effects of Botox Injections. Polo and Jabbari30 reported a patient with 
progressive supranuclear palsy was significantly handicapped by the 
degree of his rigidity. After receiving local injections of botulinum toxin in 
the upper limb muscles, the patient showed marked improvement and 
was able to move his frozen limb. There were a number of studies on the 
treatment of dystonia.12.15.24-27 Dystonia is a neurological disorder 
characterized by involuntary, sustained, intermittent or repetitive muscle 
contractions resulting in abnormal twisting or deviations of posture.26 
After receiving Botox injections, patients with many types of dystonia, 
such as blepharospasm, spasmodic torticollis and spasmodic dysphonia, 
felt relief when the abnormally contracting muscles were made to relax. 
Metzer and Jenkins22 reviewed several studies and reported significant 
benefit in 53-90 % of patients with cervical dystonia after Botox injections. 
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Even when head control was not dramatically improved, pain 
significantly decreased. In the patient who is in the advanced stage of 
Parkinson's disease, foot dystonia is frequently observed.25 The foot 
dystonia is often painful and resembles a common muscle spasm. The 
pain is probably due to sustained muscle contraction and often 
interferes with daily activities. Significant improvement of pain and 
dystonia after Botox injections was observed in the study by Pacchetti et 
al.25 Botox injections to lower extremity adductor muscles led to 
pronounced improvements in daily toilet care for a patient with multiple 
sclerosis and severe adductor spasticity.14 
In cerebral palsy, the lesion in the central nervous system often 
results in spasticity of various muscle groups.23 Due to the increase in 
tone, functional problems develop. The increased tone may also be 
responsible for the failure of longitudinal muscle growth which is 
characteristic of the condition. Botulinum Toxin-A may have a twofold 
benefit to patients with cerebral palsy: 1) reduced levels of hypertonicity 
would allow more control of movement for the duration of the toxin's 
effect and 2) increased stretch of the relaxed muscle would promote 
longitudinal growth, and reduce the incidence of degree of fixed 
contractures. In the study done by Miller and Dabney,23 parents 
reported that tone was clinically decreased in most patients, with the 
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exception of one child who had fixed contractures. Some parents even 
reported a gain of maximum range of motion. Koman et al 17 reported 
that children with cerebral palsy, who were treated with Botox, showed 
noticeable improvements in easing patient care, positioning, and 
function. The literature reflects various response times to the Botox 
injections with initial change in spasticity seen in as little as three23 days 
and effects lasting up to six months.17.19.20-22 
Some of the drawbacks of the use of Botox injection include the 
side effects that can occur. The side effects are infrequent and 
transient. When used in the treatment of blepharospasm, side effects 
have included drooping of the eyelid, blurred vision and double vision, 
which ali recovered spontaneously.16 Weakness in the injected muscle is 
the principle side effect and can impair useful motor function.26 Transient 
weakness can also occur in nearby muscle due to regional diffusion. For 
example, swallowing difficulties have been reported by those patients 
being treated for cervical dystonia.32 
Injections have to be repeated as symptomatology returns due to 
the temporary effect of Botox injections.20 Muscle recovery occurs when 
the muscle develops new extra-junctional acetylcholine receptors. 17.19 
New synaptic contacts on the adjacent muscle fiber receptors are 
formed when the terminal axon begins to sprout new branches. 
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Fast-twitch muscle is functionally denervated longer than slow-twitch 
muscle.17 Effective dosages tend to decrease and the interval between 
necessary injections tends to increase with repeated therapy.2o Because 
of the repeated injections, 10%12 of patients will develop antibodies to 
the toxin.22•26 
There are several advantages of Botox injections over surgical 
therapy in the management of intractable diseases.19 These 
advantages include 1) varied degrees of weakening can be achieved 
by varying the injected dosages and 2) the patient is awake and 
therefore you don't have the risk of anesthesia or postoperative 
infection.19.23 
Because Botox has only been used briefly in the clinic, long term 
effects are unknown but no lasting side effects have been reported. 13 
However, due to the fact that functional nerve sprouts form after each 
injection, altering the architecture of muscle innervation, more study is 
needed on the effect of repeated injections.15 
CHAPTER 4 
SELECTIVE DORSAL RHIZOTOMY 
A surgical procedure designed to reduce spasticity is selective 
dorsal rhizotomy.33 The term selective refers to the selective sectioning of 
segmental rootlets or fascicles with abnormal neurophysiologic 
characteristics and sparing of a variable proportion of rootlets with 
normal responses. The term rhizotomy is derived from the word rhizomes 
which is another term for nerve rootlet.34 
According to Walker,34 in 1898, Sherrington rendered cats spastic 
by transecting their midbrains. He then severed the posterior nerve roots 
of the spinal nerves and the spasticity disappeared, an introduction of 
the procedure referred to as selective dorsal rhizotomy. Fifteen years 
later, Foerster used the technique to reduce tone in patients with 
congenital spastic paraplegia.35 
The reasoning behind selective dorsal rhizotomy is to get a 
neurolytic reduction in afferent facilitatory influences on the anterior 
horn cell in the patient who demonstrates spasticity and has diminished 
inhibitory influences from descending tracts.36 
17 
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According to Sweetser et al,37 a revised technique was introduced 
into the United States in 1986 which had decreased complications and 
has increased the prominence of selective dorsal rhizotomy as a 
treatment for spastic cerebral palsy. The revisements have improved the 
safety and efficacy of selective dorsal rhizotomy. Peacock and Staudt38 
suggested that the principle goal of the surgery is to either improve 
functional performance or to ease the daily care routines of the person 
with spasticity. 
Selective dorsal rhizotomy has been used for both adults and 
children with various diagnoses.39 Some of these diagnoses include 
patients with multiple sclerosis, spinal cord injuries, myelomeningocele 
with tethered cord, and traumatic brain injuries.33 When selective dorsal 
rhizotomy has been applied to pediatric populations, it is most 
commonly used to treat children with cerebral palsy. 
The procedure involves a lumbosacral laminectomy and dural 
incision to expose lumbar and sacral spinal nerve roots.40 Intra operative 
electromyography is used to isolate dorsal rootlet bundles associated 
with sustained muscular contraction or with diffusion of contractions of 
muscle groups not belonging to that nerve's segmental distribution. 
Rootlet bundles (containing 3 -5 rootlets) that do not have normal 
inhibitory responses to electrical stimulation are sectioned. The rhizotomy 
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of the dorsal roots is performed between L2 - S2 but care is taken to 
avoid cutting more than two adjacent nerve roots which can cause 
excess loss of sensation.37 Fifty percent or more of rootlets may be 
sectioned at a specific root with no detectable loss of cutaneous 
sensation in corresponding dermatomes. The S3 and S4 roots are always 
avoided at all costs to spare bladder innervation.33.41 
The success of selective dorsal rhizotomy depends on the careful 
selection of patients.36 Children with spastic diplegia, who are able to 
walk independently and willing to cooperate with the rigorous physical 
therapy that will follow the surgery, are considered ideal candidates for 
selective dorsal rhizotomy.4o Children with other problems such as rigidity, 
dyskinesia or ataxia do not benefit and children with hemiplegia are 
considered too mildly involved to benefit.36 Children who have had 
insufficient anti-gravity strength to maintain their limb function without 
the spasticity in their legs would not be selected as candidates for 
selective dorsal rhizotomy for obvious reasons.42 According to 
Hendricks,43 selection criteria at the st. Louis Children's Hospital included 
diagnoses of spastic diplegia or quadriplegia in patients between the 
age of two and twenty-three years of age and no evidence of 
significant damage to basal ganglia on magnetic resonance imaging. 
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Other selection factors included good muscle strength in the legs and 
trunk, history of delayed motor development and motivation and ability 
to cooperate in therapy. As mentioned earlier, not all children benefit 
from selective dorsal rhizotomy. Individuals who are not candidates for 
the procedure include those with a history of meningitis, congenital 
infection, head trauma, severe scoliosis and those who would not be 
expected to make functional gains after surgery. 
According to Goldstein,44 selective dorsal rhizotomy is not usually 
performed until a child is at least three years old and more commonly, 
seven years old or older. Because the brain cells and the connections in 
the brain may change as the child matures, the clinicians often wait until 
a child is three years old before identifying the type and severity of his or 
her cerebral palsy. In contrast, according to McDonald,33 maximal 
functional benefit was shown to occur in preschool age children with 
spastic diplegia. This was attributed to the fact that younger patients 
may have fewer abnormal movement patterns developed and they 
tend to have fewer musculoskeletal deformities. 
Surgery always involves some risk, such as infection, unexpected 
bleeding, or side effects of anesthesia.40 The risk that the wrong nerves or 
too many nerves will be cut are additional risks of selective dorsal 
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rhizotomy. This could result in further complications and can cause new 
problems. Intraoperative complications can occur with each child who 
undergoes selective dorsal rhizotomy.43 Such complications include 
impaired skin integrity related to the surgical incision, immobility or 
improper positioning, alteration in comfort related to the surgical incision, 
alteration in urinary elimination and neuromuscular changes related to 
improper positioning. Even when appropriate nerve rootlets are cut 
some children experience sensory abnormalities, such as numbness or 
tingling in some areas of the body.40 Serious peri-operative complications 
which included bronchospasms, aspiration pneumonia, urinary retention, 
sensory loss, cerebrospinal fluid leakage, temporary loss of bowel and 
bladder function, spinal subdural hematoma and urinary tract infection 
where experienced by some patients~33.37,41,42,44 Post-operatively, the 
patient will experience a great deal of pain for several days.34,40,41.44 There 
are several components to the post-operative pain in this patient 
population: somatic pain at the operative site, dysaethesia and 
hyperaesthesia of the lower extremities, and distress and discomfort 
resulting from intermittent muscle spasms of the lower extremities.40 
According to McDonald and Hays,41 severe post-operative pain was 
reported in 58% of patients. The effect of dorsal rhizotomy documented 
in the literature provides evidence that immediately after surgery 
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selective dorsal rhizotomy reduces spasticity and increases joint range of 
movement, apparently limited by abnormal muscle tone.35.40 Gaskill and 
Steinbok45 reported decreased spasticity and improved ease of care 
taking in non-ambulatory children and improved ambulation in 
ambulatory children. Selective dorsal rhizotomy can permanently 
reduce spasticity so that the child with spastic cerebral palsy 
experiences little or no stiffness, has more normal muscle tone, and 
experiences greater ease of movement.43 Abbott et al42 noted that all 
post selective dorsal rhizotomy groups studied had statistically significant 
improvements in the tone of every muscle tested. Goniometric 
examination was significantly improved in all joints evaluated. Children 
participating in this study experienced dramatic decreases in leg muscle 
tone and corresponding improvements in passive range of motion in 
their lower extremities one year after surgery. Staudt and Peacock39 
stated that functional improvements have been more difficult to 
quantify, but rating of gross motor skills has revealed improvements in 
developmental postures, transitional movements, and walking abilities. 
When improvement occurs, it may be different for each child.44 
Children with spastic diplegia may be able to stand with their feet flat on 
the floor, and may also make gains in walking, climbing stairs or self-care 
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tasks following selective dorsal rhizotomy. According to Goldstein,44 
some report improvement in skills that include upper body movements 
which are probably related to an improvement in overall balance and 
stability. Improvement in sitting or in the ability to transfer from one 
seated position to another has been seen in children with spastic 
quadriplegia following selective dorsal rhizotomy. Children may also 
improve in self-care skills and be less dependent on the assistance of 
others. 
According to Goldstein,44 not all children improve after selective 
dorsal rhizotomy and some even lose ground. Giuliani35 reviewed 
several studies and reported a decrease in strength in the lower limbs 
initially following selective dorsal rhizotomy. Strength levels, however, 
gradually increased resulting in improved function. Abbott et al42 
reported significant deterioration in plantar flexor ranges, for some 
subjects, between six and twelve month examinations. Dudgeon et al36 
stated that some children, who lacked voluntary muscle control or 
strength, might have learned to use their spasticity to support upright 
stance, sitting or hand placement. After selective dorsal rhizotomy, 
retraining may be unsuccessful and therefore result in a loss of function 
or difficulty and delay in resuming previous levels of function. McDonald 
and Hays41 reported that after three years, 5% of patients had 
I 
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recurrence of spasticity and an additional 2.5% had recurrence when 
followed fifteen years after selective dorsal rhizotomy. 
Children with cerebral palsy are at risk of developing a 
symptomatic neurogenic bladder.42 Symptoms suggestive of neurogenic 
bladder include enuresis, stress incontinence, and dribbling. The 
reduction in spasticity following selective dorsal rhizotomy can also result 
in a hypotonic bladder requiring intermittent catheterization on either a 
temporary or permanent basis. Selective dorsal rhizotomy reduces 
spasticity but does not have a direct effect on balance, abnormal 
movement patterns, or persistent tonic reflexes.43 Perhaps the most 
important factors influencing outcomes are the child's motivation, 
cooperation, and intelligence and the level of family support available 
as the child gains new skills. Objective evaluation of treatment outcome 
in cerebral palsy remains a challenge.33 To date, most of the evaluation 
of progress after selective dorsal rhizotomy has been subjective in 
nature. 
Following selective dorsal rhizotomy, weakness, primitive 
movement patterns, and impaired motor control persist.33 For this reason, 
intensive therapy appears necessary to maximize ultimate functional 
gains. McDonald and Hays41 suggested that intensive and consistent 
physical therapy, tailored to the needs of the individual child, is essential 
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to ensure maximum physical progress and functional gain during the 
postoperative period. 
The literature suggests that selective dorsal rhizotomy can be 
useful for spasticity in cerebral palsy when patients are carefully 
selected.41 Younger children with spastic diplegia, who are seriously 
impaired by spasticity but have retained good selective motor control 
and some degree of forward locomotion appear to make the most 
functional gains in uncontrolled studies. Pre-operatively, physical 
therapists also rule out candidates who have motor impairment due to 
dystonia, athetosis, ataxia, and abnormal reflex posturing,34 who would 
not be good candidates for the surgical procedure. It is, however, very 
difficult to make decisions with absolute confidence regarding who 
should receive selective dorsal rhizotomy and therapy.36 Further 
clarification is needed to determine which children have the most to 
gain from the reduction of spasticity. The long term effects of rhizotomy 
have not been documented and questions remain as to whether the 
weakening that inherently accompanies rhizotomy will be 
counterproductive as age and weight advance.45 
CHAPTER 5 
CONCLUSION 
Spasticity is very complex and not completely understood. 
Physical therapists are often faced with this phenomenon that is 
observed in many types of patients. Some patients who often show signs 
of spasticity include those who have suffered from spinal cord injuries, 
strokes and cerebral palsy. A person's disability may be greatly 
increased secondary to spasticity. Depending on the cause, clinical 
characteristics may vary in signs and severity. Spasticity may interfere 
with function, limit a person's independence and may cause secondary 
complications such as contractures. 
Although spasticity presents major problems in the restoration of 
motor function, it is important to realize that spasticity may be beneficial 
in some patients in carrying out basic activities of daily living. Physical 
therapists playa vital role in the treatment of spasticity. They will not be 
the ones to prescribe Botox injections or selective dorsal rhizotomy but a 
therapist's observation can help determine if in fact the spasticity is 
disabling or of benefit to the patient. 
26 
27 
When it has been determined that the patient's spasticity is so 
severe and is causing multiple complications that interfere with activities 
of daily living, medical management will become necessary. Two 
options for the treatment of spasticity include Botox injections and 
selective dorsal rhizotomy. The choice of treatment will depend on the 
severity of the spasticity, the goals to be achieved with spasticity 
reduction and criteria for patient selection. 
Botox injection therapy is a more conservative treatment form 
than selective dorsal rhizotomy. Botox is injected directly into the 
affected muscle(s) whereas selective dorsal rhizotomy is a surgical 
procedure that requires the cutting of sacral spinal nerve roots. 
Unlike Botox, in which effects last temporarily unless use is 
continued and/or repeated, selective dorsal rhizotomy is permanent 
and irreversible due to nerve rootlet severing. Botox can be used in 
patients who exhibit many types of dystonia whereas selective dorsal 
rhizotomy is not recommended. Botox can be used in spastic muscles of 
the upper and lower extremity and selective dorsal rhizotomy is used 
when lower extremity spasticity is problematic. 
There are documented side effects with the use of Botox but these 
are infrequent and transient. There are also advantages of using Botox 
injections over surgical intervention, one of which is that there is no risk 
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secondary to the use of anesthesia which is required in selective dorsal 
rhizotomy but not with the use of Botox injection. 
With selective dorsal rhizotomy, there is risk of cutting too many or 
the wrong nerve rootlets, resulting in permanent secondary 
complications such as an alteration in urinary elimination. With Botox 
injections the most effective dose per muscle is not known and there is 
risk of transient weakness in nearby muscles due to regional diffusion. 
However, this weakness is only temporary. 
Botox use in the clinic has been very limited and long term effects 
are unknown. New nerve sprouts form after injection and these sprouts 
can alter the architecture of muscle enervation. The consequences 
from this require more study. Selective dorsal rhizotomy has been 
around for many years and revised techniques have improved upon its 
safety and efficacy. However, not all patients improve functionally and 
the question remains if the procedure is counterproductive as the age 
and weight of the patient advances. 
In conclusion, compelling evidence has been presented in the 
literature showing that even when spasticity is reduced there may be no 
improvement of function. Therapists need to be aware of this and 
realize that reducing the tone may increase the range of motion, but 
may unmask underlying weakness rather than underlying control. 
REFERENCES 
1. Katz RT, Rymer WZ. Spastic Hypertonia: Mechanisms and 
Measurement. Arch Phys Med Rehabil. 1989;70:144-155. 
2. Firoozbakhsh KK, Kunkel CF, Scremin AM, Moneim MS. Isokinetic 
Dynamometric Technique For Spasticity Assessment. Am J Phys Med 
Rehabil. 1993;72:379-385. 
3. St. George CL. Spasticity Mechanisms and Nursing Care. Neurosci 
Nurs. 1993;28:819-827. 
4. Katz RT. Management of Spasticity. Am J Phys Med Rehabil. 
1988;67:108-114. 
5. Howe T, Oldham J. Measuring Muscle Tone and Movement. Nurs 
Stan. 1995;9:25-29. 
6. Lance JW. Cited by: Kayz RT, Zev R. Spastic Hypertonia: Mechanisms 
and Measurement. Arch Phys Med Rehabil. 1989;70: 144-154. 
7. Leonard CT. Motor Behavior and Neurol Changes Following Perinatal 
and Adult-Onset Brain Damage: Implications for Therapeutic 
Interventions. Clin Pers. 1994;74:753-766. 
8. Malouin F, Boiteau M, Bonneau C, Pichard L, Bravo G. Use Of A 
Hand-Held Dynamometer For Evaluation Of Spasticity In A Clinical 
Setting: A Reliability Study. Physio Can. 1989;41 :126-129. 
9. Webster, M. Third New International Dictionary. Springfield Ma: 
Merrian-Webster Inc.;1994:426. 




11. Pearce LB, Borodic GE, Johnson EA, First ER, Maccallum R. The Median 
Paralysis Unit: A More Pharmacologically Relevant Unit of Biologic 
Activity For Botulinum Toxin. Toxicon. 1995;33:217-227. 
12. Vangelova L, "A Poison That Can Heal." 
http://www.fda.gov/fdac/features/095_bot.html. (5 Aug. 1996). 
13. II Botulinum Toxin." 
http://www.kumc.edu/instruction/medicine/neurology/botox.html. (5 
Aug. 1996). 
14. Giladi N, Meer J, Kidan C, Greenberg E, Gross B, Honigman S. 
Interventional Neurology: Botulinum Toxin As A Potent Symptomatic 
Treatment In Neurology. Isr J Med Sci. 1994;30:816-819. 
15. Cichon JV, McCaffrey TV, Litchy WJ, Knops JL. The Effect Of Botulinum 
Toxin Type A Injection On Compound Muscle Action Potential In An In 
Vivo Rat Model. Laryngoscope. 1995;105:144-148. 
16. II Botulinum Toxin Injections." 
http://www.zipnet.net/users/dystonia/blephar1.html#A7. (5 Aug.1996). 
17. Koman LA, Mooney JF, Smith B, Goodman A, Mulvaney T. 
Management Of Cerebral Palsy With Botulinum-A Toxin Preliminary 
Investigation. J Pediatr Orthop. 1993;13:489-495. 
18. Murry T and Woodson, GE. Combined-Modality Treatment of 
Adductor Spasmodic Dysphonia with Botulimum Toxin and Voice 
Therapy. J Voice. 1995;9:460-465. 
19. Epperson LW. Therapeutic Uses of Botulinum Toxin (Botox). Ala Med. 
1995;65:49-50. 
20. Cook MJ and Lewin JS. Spasmodic Dysphonia: New Diagnosis and 
Treatment Opportunities. Nurse Pract. 1994;19:67-73. 
21. Green DC, Ward PH, Berke GS, Gerratt BR. Point-Touch Technique Of 
Botulinum Toxin Injection For The Treatment Of Spasmodic Dysphonia. 
Ann Otol Rhino! Laryngol. 1992; 101 :883-887. 
31 
22. Metzer WS, Jenkins T. Treatment Of Cervical Dystonia (torticollis) In 
Adults With Botulinum A Toxin. J Ark Med Soc. 1992;89:133-134. 
23. Miller F, Dabney K. "Botulinum Toxin-A In The Management Of 
Children With Cerebral Palsy." 
http:// gait .aidi .udel.ed u /res69 5/homepage /pd_ ortho /research/ 
symp_695/newsched.htm (5 Aug. 1196). 
24. Jankovic J, Schwartz K. Botulinum Toxin Treatment Of Tremors. 
Neurology. 1991 ;41 : 1185-1188. 
25. Pacchetti C, Albani G, Martignoni E, Godi l, Alfonsi E, Nappi G. "Off" 
Painful Dystonia In Parkinson's Disease Treated With Botulinum Toxin. 
Mov Disord. 1995;10:333-336. 
26. Cheshire Wp, Abashian SW, Mann JD. Botulinum Toxin In The 
Treatment Of Myofascial Pain Syndrome. Pain. 1994;59:65-69. 
27. "Dystonia." http://www.kumc.edu/instruction/medicine/neurology / 
dystonia.html (5 Aug. 1996). 
28. Pisik B. "Botulinum Toxin Works As Poison, Therapy, and Beauty Aid." 
http://www.healthweek.com/features/botox.html(5 Aug. 1996). 
29. Ogilvie J, Hylind l, Kress l, McEwen D, Vaughn C. Botulinum Toxin: A 
New Therapeutic Use. Gastroenterology Nurs. 1995;18:92-95. 
30. Polo KB, Jabbari B. Botulinum Toxin-A Improves The Rigidity Of 
Progressive Supranuclear Palsy. Ann Neurol. 1994;35:237-239. 
31. Comella Cl, Buchman AS, Tanner CM, Brown-Toms NC, Goetz CG. 
Botulinum Toxin Injections For Spasmodic Torticollis: Increased 
Magnitude Of Benefit With Electromyographic Assistance. Neurology. 
1992;42:878-882. 
32. Comella Cl, Tanner CM, DeFoor-Hili L, Smith C. Dysphagia After 
Botulinum Toxin Injections For Spasmodic Torticollis: Clinical And 
Radiologic Findings. Neurology. 1992;42:1307-1310. 
32 
33. McDonald CM. Selective Dorsal Rhizotomy A Critical Review. Phys 
Med Rehabil Clin North Am. 1991;2:891-915. 
34. Walker MJ. Selective Dorsal Rhizotomy Reducing Spasticity In Patients 
With Cerebral Palsy. AORN. 1991 ;54:759-772. 
35. . Giuliani CA. Dorsal Rhizotomy For Children With Cerebral Palsy: 
Support For Concepts Of Motor Control. Phys Ther. 1991 ;71 :248-259. 
36. Dudgeon BJ, Libby AK, McLaughlin JF, Hays RM, Bjornson KF, Roberts TS. 
Prospective Measurement Of Functional Changes After Selective 
Dorsal Rhizotomy. Arch Phys Med Rehabil. 1994;75:46-53. 
37. Sweetser PM, Badell A, Schneider S, Badlani GH. Effects Of Sacral 
Dorsal Rhizotomy On Bladder Function In Patients With Spastic 
Cerebral Palsy. Neurol Urodyn. 1995;14:57-64. 
38. Peacock WJ, Staudt LA. Cited by: Dudgeon BJ, Libby AK, McLaughlin 
JF, Hays RM, Bjornson KF, Roberts TS. Prospective Measurement Of 
Functional Changes After Selective Dorsal Rhizotomy. Arch Phys Med 
Rehabil. 1994;75:46-53. 
39. Staudt LA, Peacock WJ. Dorsal Rhizotomy For Spasticity. West J Med. 
1995;162:260-261. 
40. Geiduschek JM, Haberkern CM, McLaughlin JF, Jacobson LE, Hays RM, 
Roberts TS. Pain Management For Children Following Selective Dorsal 
Rhizotomy. Can J Anaesth. 1994;41 :492-496. 
41. McDonald CM, Hays RM. Selective Dorsal Rhizotomy: Patient 
Selection, Intraoperative Electrophysiologic Monitoring, And Clinical 
Outcome. Phys Med Rehabil. 1994;8:579-605. 
42. Abbott R, Johann-Murphy M, Shiminski-Maher T, Quartermain 0, Forem 
SL, Gold JT, Epstein F J. Selective Dorsal Rhizotomy: Outcome And 
Complications In Treating Spastic Cerebral Palsy. Neurosurgery. 
1993;33:851-857. 
43. Hendricks-Ferguson, Ortman. Selective Dorsal Rhizotomy To Decrease 
Spasticity In Cerebral Palsy. AORN. 1995;61 :514-525. 
33 
44. Goldstein. Selective Dorsal Rhizotomy. Exceptional Parent. 
1995;25:41-45. 
45. Thompson JD. Orthopedic Aspects Of Cerebral Palsy. Curr Opin Peds. 
1994;6:94-98. 
